Laurus Labs Limited share price

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosage…Read more

Website NSE BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty 500 Nifty Midcap 150NSE: LAURUSLABSISIN INE947Q01028

16 Oct 2026, 3:29 PM IST₹2,060.10▲ 41.60 (2.06%)

Market Cap₹ 1,11,310 Cr.
Current Price₹ 2,060.10
High / Low₹ 2,086 / 870
Stock P/E101.8
Book Value₹ 98
Dividend Yield0.12 %
ROCE19.5 %
ROE18.20 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 20.23
Price / Book20.98
OPM19.4 %
Debt / Equity0.48
Sales growth (5Y)7.2 %
Profit growth (5Y)-2.0 %
Promoter holding32.0 %
EV / EBITDA55.7
Beta0.34
All-time high₹ 2,069

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
LAURUSLABS	+8.11%	+32.26%	+82.58%	+85.93%	+136.02%	+72.84%	+26.17%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Laurus Labs Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,11,310 crore.
It trades at 101.8 times its last 12 months' earnings and 21.0 times book value.
Revenue grew 7.2% a year over the last 5 years, profit -2.0% a year.
Return on equity was 18.2% and return on capital employed 19.5% in the latest year.
Debt was 0.48 times shareholders' equity.
The share price is 1.2% below its 52-week high and up 136.0% over one year.
Promoters and insiders hold about 32.0%; institutions about 33.9%.

Pros

Latest quarter (Jun 2026): sales up 29% and profit up 124% from a year ago.
Institutional (FII + DII) holding has risen by 6.7 points over 3 years.

Cons

Profit growth has been weak: -2.0% a year over the last 5 years.
Trades at 21.0 times its book value.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Laurus Labs Limited

Employees: 7,059
Head office: Hyderabad
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty 500 Nifty Midcap 150

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	7.2
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,835	54.57	9.1	27.1	18.39	25.0	1.79	63.18	13,753	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
7.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
8.	Abbott India	26,170.00	34.4	55,609	2.01	429	17.13	1,814	4.33	41.9	34.5	11.65	26.3	0.04	75.54	6,927	9.0
9.	Ipca Laboratories	1,832.60	35.5	46,494	0.31	424	82.18	2,788	20.76	16.4	15.2	5.77	17.0	0.10	45.06	9,646	15.5
10.	Ajanta Pharma	3,329.00	36.7	41,599	1.91	334	48.37	1,626	38.92	29.4	25.4	9.19	24.5	0.06	54.29	5,407	13.4
	Median: 14 Co.	1,946.35	34.4	79,158	0.67	505	25.89	3,958	19.95	18.5	16.5	5.41	20.6	0.08	53.15	12,114	11.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,182	1,224	1,195	1,440	1,195	1,224	1,415	1,720	1,570	3,223	1,778	1,812	2,026
YOY Sales Growth %	-23.21%	-22.30%	-22.65%	4.26%	1.11%	-0.06%	18.42%	19.49%	31.35%	163.38%	25.67%	5.31%	29.10%
	1,015	1,037	1,014	1,198	1,024	1,045	1,130	1,300	1,187	2,438	1,298	1,299	1,388
Material Cost %	49%	47%	46%	50%	45%	45%	43%	45%	41%	40%	39%	39%	37%
Employee Cost %	14%	13%	13%	11%	15%	15%	13%	10%	14%	13%	13%	13%	13%
Other Expenses %	23%	24%	26%	22%	26%	26%	23%	20%	21%	22%	21%	20%	18%
Operating Profit	167	188	181	241	171	178	285	421	382	785	480	512	638
OPM %	14%	15%	15%	17%	14%	15%	20%	24%	24%	24%	27%	28%	31%
Other Income	4	2	2	19	3	5	9	59	10	37	6	12	9
Interest	39	42	51	51	49	53	58	56	52	92	39	40	42
Depreciation	91	93	98	102	106	108	106	110	117	237	121	122	124
Profit before tax	41	54	35	107	18	23	131	312	224	494	327	361	481
	30%	27%	27%	30%	34%	22%	31%	25%	28%	28%	22%	22%	25%
Current tax	16	15	18	43	18	23	35	80	60	148	71	78	135
Deferred tax	-4	-1	-9	-11	-12	-18	5	-2	3	-9	2	1	-16
	27	37	23	75	13	20	93	233	162	356	252	282	362
Profit from associates	-2	-2	-2	-0	0	2	2	-1	1	1	-1	0	0
Minority share	2	0	0	-1	0	0	1	-1	-1	-2	0	3	-6
Profit to shareholders	25	37	23	76	13	20	92	234	163	358	252	279	368
YOY Profit Growth %	-89.38%	-84.10%	-88.48%	-28.74%	-52.67%	-46.26%	298.20%	210.28%	1,175.08%	1,685.31%	171.01%	21.19%	123.94%
EPS in Rs	0.46	0.69	0.43	1.40	0.23	0.37	1.71	4.34	3.02	6.63	4.67	5.17	6.81
Raw filing

₹ Cr	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026	Jun 2026
	1,279	1,108	1,158	1,132	1,415	1,117	1,185	1,265	1,650	1,433	1,509	1,580	1,757
YOY Sales Growth %		-25.92%	-22.70%	-24.56%	10.57%	0.84%	2.32%	11.75%	16.65%	28.28%	19.30%	-4.22%	22.64%
	1,027	980	978	962	1,143	956	1,003	1,059	1,255	1,105	1,164	1,205	1,258
Material Cost %	52%	53%	49%	47%	51%	47%	47%	47%	47%	43%	41%	43%	41%
Employee Cost %	9%	12%	12%	12%	10%	13%	13%	13%	9%	13%	13%	13%	12%
Other Expenses %	20%	23%	23%	26%	20%	26%	25%	23%	20%	22%	23%	21%	18%
Operating Profit	252	128	181	170	271	161	182	206	395	327	346	375	499
OPM %	20%	12%	16%	15%	19%	14%	15%	16%	24%	23%	23%	24%	28%
Other Income	6	7	6	11	24	9	12	7	72	22	14	13	20
Interest	41	33	38	38	42	41	45	48	49	44	31	34	35
Depreciation	81	84	85	87	89	91	91	89	88	94	94	95	96
Profit before tax	137	17	63	57	164	39	58	77	330	211	234	259	388
	25%	24%	26%	25%	26%	26%	27%	25%	24%	25%	25%	26%	25%
Current tax	7	6	18	17	46	17	22	33	82	60	69	69	103
Deferred tax	27	-2	-2	-3	-3	-7	-6	-13	-4	-6	-10	-1	-5
	102	13	47	43	121	29	42	57	252	158	175	192	290
YOY Profit Growth %		-94.36%	-79.48%	-78.58%	18.62%	120.20%	-9.06%	34.31%	107.63%	448.78%	205.71%	-23.86%	83.59%
EPS in Rs	1.89	0.48	0.87	0.79	2.25	0.53	0.79	1.06	4.68	2.93	3.25	3.55	5.37
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	2,069	2,069	2,292	2,832	4,814	4,936	6,041	5,041	5,554	6,813	8,839
YOY Sales Growth %			10.77%	23.55%	69.99%	2.54%	22.39%	-16.55%	10.18%	22.67%
	1,656	1,656	1,936	2,267	3,263	3,513	4,448	4,263	4,499	5,035	6,423
Material Cost %	51%	51%	54%	50%	45%	44%	46%	48%	45%	40%	39%
Employee Cost %	12%	12%	13%	12%	9%	10%	10%	13%	13%	13%	13%
Other Expenses %	16%	16%	18%	18%	14%	17%	18%	24%	23%	21%	21%
Operating Profit	413	413	356	565	1,551	1,422	1,592	778	1,055	1,778	2,416
OPM %	20%	20%	16%	20%	32%	29%	26%	15%	19%	26%	27%
Other Income	29	29	16	6	24	15	6	26	75	55	64
Interest	80	80	88	90	68	102	165	183	216	171	213
Depreciation	125	125	164	187	205	251	324	385	430	480	604
Profit before tax	237	237	120	294	1,301	1,084	1,109	236	484	1,182	1,663
	29%	29%	22%	13%	24%	23%	28%	29%	27%	25%	25%
Current tax	53	53	25	54	338	254	290	93	157	298
Deferred tax	17	17	1	-15	-20	-3	22	-25	-27	-5
	168	168	94	255	984	832	793	162	358	890	1,252
Profit from associates						-0	-3	-6	4	0	0
Minority share						5	3	2	0	1	-4
Profit to shareholders						828	790	161	358	889	1,256
YOY Profit Growth %			-44.06%	172.25%	285.40%	-15.41%	-4.66%	-79.55%	120.83%	148.41%
EPS in Rs	3.17	3.17	1.77	4.79	18.36	15.42	14.69	2.98	6.65	16.47	23.28
Dividend Payout %							14%	54%	12%	10%

Compounded Sales Growth

5 Years:: 7%
3 Years:: 4%
TTM:: 49%

Compounded Profit Growth

5 Years:: -2%
3 Years:: 4%
TTM:: 147%

Stock Price CAGR

5 Years:: 26%
3 Years:: 73%
1 Year:: 136%

Return on Equity

4 Years:: 13%
Last Year:: 18%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2,039	2,236	2,797	4,769	4,707	5,773	4,812	5,217	6,089
YOY Sales Growth %		9.65%	25.10%	70.47%	-1.29%	22.66%	-16.65%	8.41%	16.72%
	1,631	1,885	2,227	3,259	3,422	4,292	4,063	4,273	4,651
Material Cost %	52%	54%	50%	46%	47%	47%	50%	47%	42%
Employee Cost %	12%	12%	12%	8%	9%	9%	11%	12%	12%
Other Expenses %	16%	18%	18%	14%	16%	19%	23%	23%	22%
Operating Profit	409	351	570	1,510	1,285	1,482	750	944	1,438
OPM %	20%	16%	20%	32%	27%	26%	16%	18%	24%
Other Income	29	16	6	27	22	16	47	100	77
Interest	75	86	88	66	96	146	151	182	143
Depreciation	121	161	184	197	235	301	345	359	379
Profit before tax	241	121	304	1,275	975	1,051	301	504	994
	28%	22%	12%	25%	23%	28%	26%	24%	26%
Current tax	53	25	53	335	231	271	88	154	285
Deferred tax	15	1	-16	-16	-6	20	-10	-30	-32
	173	95	267	956	750	760	224	380	740
YOY Profit Growth %		-45.13%	181.12%	258.03%	-21.55%	1.37%	-70.58%	70.04%	94.66%
EPS in Rs	3.27	1.79	5.01	17.85	13.97	14.14	4.15	7.06	13.72
Dividend Payout %						14%	39%	11%	12%

Compounded Sales Growth

5 Years:: 5%
3 Years:: 2%

Compounded Profit Growth

5 Years:: -5%
3 Years:: -1%

Stock Price CAGR

5 Years:: 26%
3 Years:: 73%
1 Year:: 136%

Return on Equity

4 Years:: 13%
Last Year:: 18%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	108	108	108	108
Reserves	3,930	4,003	4,365	5,192
	2,015	2,577	2,764	2,518
Long term borrowings	761	798	646	611
Short term borrowings	1,211	1,709	2,048	1,786
	1,608	1,699	2,099	2,693
Trade payables	711	1,051	958	1,252
Minority interest	11	5	130	131
Current liabilities	2,432	3,112	3,540	3,635
Total Liabilities	7,660	8,387	9,336	10,511
	3,700	4,048	4,316	4,879
Gross block	5,058	5,764	6,412	7,393
Accumulated depreciation	1,357	1,717	2,096	2,513
Goodwill & intangibles	259	265	266	265
CWIP	551	423	458	773
	3,409	3,917	4,561	4,859
Inventories	1,685	1,845	1,937	2,342
Trade receivables	1,580	1,663	2,007	2,155
Cash & equivalents	46	139	100	113
Current assets	3,462	3,835	4,332	4,829
Total Assets	7,660	8,387	9,336	10,511

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	994	666	602	1,624
Profit for the year	790	161	358	889
Working capital changes	-315	-29	-375	25
Direct taxes paid	-285	-105	-138	-294
	-996	-822	-682	-1,089
Fixed assets purchased	-990	-678	-641	-1,070
Fixed assets sold	3	2	100	7
	-27	250	39	-525
Proceeds from borrowings	468	758	487	255
Repayment of borrowings	-247	-217	-316	-572
Interest paid	-140	-174	-209	-171
Dividends paid	-107	-86	-43	-86
Net Cash Flow	-29	93	-41	10
Free Cash Flow	4	-13	-39	554

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	19.6%	3.9%	8.3%	18.2%
ROCE	23.6%	7.7%	11.9%	19.5%
Operating margin	21.5%	7.9%	11.4%	19.4%
Net margin	13.1%	3.2%	6.5%	13.2%
Debt / equity	0.50	0.63	0.62	0.48
Current ratio	1.42	1.23	1.22	1.33

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities).

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 27.47%
FIIs 28.00%
DIIs 13.74%
Public 30.78%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	27.20%	27.19%	27.19%	27.18%	27.18%	27.62%	27.62%	27.59%	27.59%	27.49%	27.49%	27.47%
	24.03%	25.39%	25.97%	25.67%	26.08%	25.56%	25.52%	25.70%	26.16%	26.52%	25.82%	28.00%
Foreign portfolio investors (Cat. I)	23.27%	24.65%	25.18%	24.85%	25.02%	24.35%	24.04%	24.22%	24.73%	25.22%	24.78%	26.65%
Foreign portfolio investors (Cat. II)	0.76%	0.74%	0.80%	0.82%	1.06%	1.21%	1.47%	1.48%	1.44%	1.30%	1.04%	1.35%
	11.01%	11.14%	11.77%	13.56%	13.05%	12.74%	11.77%	11.94%	11.73%	12.43%	13.97%	13.74%
Mutual funds	5.29%	5.58%	6.68%	9.18%	8.25%	7.62%	6.88%	7.78%	8.53%	9.49%	11.22%	10.15%
Insurance companies	5.41%	5.19%	4.75%	3.94%	4.06%	4.08%	3.63%	2.76%	1.76%	1.52%	1.50%	2.32%
Banks	0.01%											0.01%
Alternative investment funds	0.30%	0.35%	0.35%	0.44%	0.74%	1.04%	1.27%	1.39%	1.43%	1.41%	1.24%	1.25%
	37.76%	36.29%	35.07%	33.59%	33.69%	34.08%	35.09%	34.77%	34.51%	33.56%	32.71%	30.78%
Retail (up to ₹2 lakh)	16.80%	15.97%	15.13%	14.01%	13.93%	13.90%	14.40%	14.21%	14.10%	13.65%	13.26%	12.64%
HNIs (above ₹2 lakh)	9.69%	9.05%	8.82%	8.67%	8.74%	8.82%	9.24%	8.91%	9.24%	8.99%	7.99%	7.85%
NRIs	1.95%	1.89%	1.90%	1.90%	2.01%	2.01%	1.93%	1.86%	1.57%	1.41%	1.33%	1.25%
Bodies corporate	8.01%	8.14%	8.01%	7.82%	7.82%	8.16%	8.26%	8.52%	8.39%	8.30%	8.23%	7.79%
No. of Shareholders	4,02,640	3,82,880	3,56,830	3,24,059	3,09,063	2,92,214	2,92,905	2,80,223	2,83,678	2,80,756	2,92,281	2,91,653

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 29 Oct 2026
Ex-dividend date: 8 May 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Laurus Labs Limited

What is the share price of Laurus Labs Limited today?

Laurus Labs Limited (LAURUSLABS) last traded at ₹2,060.10 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Laurus Labs Limited?

About ₹1,11,310 crore at the latest price.

What is the P/E ratio of Laurus Labs Limited?

About 101.8 times its earnings over the last 12 months.

Is Laurus Labs Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Laurus Labs Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Laurus Labs Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Laurus Labs Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Laurus Labs Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next